Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
In Reply: Dr Finucane points out that the safety
profiles of celecoxib and standard NSAIDs are roughly comparable at 12 months.
It is unclear why gastric ulcerative changes would differ at 6 or 12 months
or whether the same can be said for rofcoxib, another COX-2 inhibitor.1 Nonetheless, physicians should consider the drugs'
equivalent therapeutic benefits and cost differentials when chosing a specific
NSAID for individual patients.
Lonner JH. Pain Management in Patients With Osteoarthritis—ReplyPain Management in Patients With Osteoarthritis—Reply. JAMA. 2003;290(1):36. doi:10.1001/jama.290.1.36-a